MY200609A - Antibodies binding to vista at acidic ph - Google Patents

Antibodies binding to vista at acidic ph

Info

Publication number
MY200609A
MY200609A MYPI2019004903A MYPI2019004903A MY200609A MY 200609 A MY200609 A MY 200609A MY PI2019004903 A MYPI2019004903 A MY PI2019004903A MY PI2019004903 A MYPI2019004903 A MY PI2019004903A MY 200609 A MY200609 A MY 200609A
Authority
MY
Malaysia
Prior art keywords
acidic
vista
antibodies binding
antibodies
human vista
Prior art date
Application number
MYPI2019004903A
Other languages
English (en)
Inventor
Robert J Johnston
Arvind Rajpal
Paul O Sheppard
Luis Borges
Andrew Rankin
Keith Sadoon Bahjat
Alan J Korman
Andy X Deng
lin hui Su
Ginger RAKESTRAW
Original Assignee
Five Prime Therapeutics Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Bristol Myers Squibb Co filed Critical Five Prime Therapeutics Inc
Publication of MY200609A publication Critical patent/MY200609A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MYPI2019004903A 2017-03-14 2018-03-13 Antibodies binding to vista at acidic ph MY200609A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471196P 2017-03-14 2017-03-14
US201862636746P 2018-02-28 2018-02-28
PCT/US2018/022230 WO2018169993A1 (en) 2017-03-14 2018-03-13 Antibodies binding to vista at acidic ph

Publications (1)

Publication Number Publication Date
MY200609A true MY200609A (en) 2024-01-05

Family

ID=63522565

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019004903A MY200609A (en) 2017-03-14 2018-03-13 Antibodies binding to vista at acidic ph

Country Status (18)

Country Link
US (3) US11603406B2 (https=)
EP (1) EP3595720A4 (https=)
JP (3) JP7211961B2 (https=)
KR (2) KR102715540B1 (https=)
CN (2) CN118894937A (https=)
AU (2) AU2018236218B2 (https=)
BR (1) BR112019019108A2 (https=)
CA (1) CA3054067A1 (https=)
CL (2) CL2019002610A1 (https=)
CO (1) CO2019010943A2 (https=)
IL (2) IL269240B1 (https=)
MX (1) MX2024003316A (https=)
MY (1) MY200609A (https=)
PE (2) PE20250933A1 (https=)
SG (1) SG11201907848YA (https=)
TW (2) TWI890190B (https=)
WO (1) WO2018169993A1 (https=)
ZA (1) ZA201905525B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP6124800B2 (ja) 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
ES2812208T3 (es) * 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
KR102715540B1 (ko) * 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
WO2018217976A1 (en) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antagonistic cd40 monoclonal antibodies and uses thereof
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
BR112021000303A2 (pt) * 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
KR102767692B1 (ko) * 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EP4031575A1 (en) * 2019-09-19 2022-07-27 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
MX2022007479A (es) 2019-12-18 2022-06-29 Hoffmann La Roche Anticuerpos anti-ccl2 biespecificos.
WO2022178203A1 (en) * 2021-02-18 2022-08-25 Kineta, Inc. Anti-vista antibodies and uses thereof
IL310292A (en) 2021-07-22 2024-03-01 Univ Dundee Medicinal myotains

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5605821A (en) 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
DK0714912T3 (da) 1990-07-17 2003-02-03 Univ Oklahoma Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
DE69333346T2 (de) 1992-10-23 2004-10-07 Inst Genetics Llc Neuartiges p- selectin ligandenprotein
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
EP0668907A1 (en) 1992-11-16 1995-08-30 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
WO1995030001A2 (en) 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein
EP0850243B1 (en) 1995-08-03 2003-10-08 Board Of Regents Of The University Of Oklahoma o-glycan inhibitors of selectin mediated inflammation
AU716154B2 (en) 1995-09-01 2000-02-17 University Of Washington Interactive molecular conjugates
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1040117A4 (en) 1997-12-18 2005-03-09 Human Genome Sciences Inc 110 HUMAN SECRETED PROTEINS
CA2331386A1 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
AU5249700A (en) 1999-07-08 2001-01-30 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
US6852497B2 (en) 2000-03-24 2005-02-08 Genetics Institute, Llc Methods of identifying compounds which inhibit binding of SLIC-1 to PSGL-1
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
CN1985000B (zh) 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
WO2006012232A1 (en) 2004-06-24 2006-02-02 Mayo Foundation For Medical Education And Research B7-h5, a costimulatory polypeptide
US8236304B2 (en) 2005-04-25 2012-08-07 Trustees Of Dartmouth College Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity
US8231872B2 (en) 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
WO2007033959A2 (en) 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
US7655778B2 (en) 2006-02-28 2010-02-02 Curonix Co., Ltd. SISP-1, a novel p53 target gene and use thereof
WO2008043821A1 (en) * 2006-10-11 2008-04-17 Ablynx N. V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
EP2183028A2 (en) 2007-07-25 2010-05-12 AstraZeneca AB Targeted binging agents directed to kdr and uses thereof - 035
NZ587440A (en) 2008-02-05 2013-01-25 Pfizer Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
WO2009140623A2 (en) 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
EP2389192A4 (en) * 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
US9464284B2 (en) 2009-03-09 2016-10-11 Bioatla, Llc Mirac proteins
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
EP2563391B1 (en) 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
CA2853412C (en) * 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
CA2857019C (en) 2011-11-28 2022-08-16 Gray D. Shaw Soluble tandem selectin glycoprotein ligand molecules
KR101721678B1 (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
DK3421486T5 (da) 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
BR112015029395A2 (pt) 2013-05-24 2017-09-19 Medimmune Llc Anticorpos anti-b7-h5 e seus usos
SG11201509982UA (https=) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
RS63295B1 (sr) * 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
AU2015206189B2 (en) 2014-01-14 2019-06-20 Kings College London VISTA antagonist and methods of use
RU2550262C1 (ru) 2014-02-28 2015-05-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело
WO2015187359A1 (en) 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
PT3166636T (pt) 2014-07-08 2021-06-29 Sanford Burnham Med Res Inst Moduladores de psgl-1 e utilizações dos mesmos
JOP20150008B1 (ar) * 2014-11-26 2021-08-17 Janssen Pharmaceutica Nv أجسام مضادة ل vista وأجزاء منها
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
TN2019000101A1 (en) * 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017078839A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
SG11201805557SA (en) 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
US10899836B2 (en) * 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017181109A1 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
EP3494141A4 (en) 2016-08-03 2020-04-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
KR102715540B1 (ko) * 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
WO2018195772A1 (en) 2017-04-25 2018-11-01 Sun Yat-Sen University Pd-1h as target in treatement of asthma
CA3067835A1 (en) 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
MX2020005495A (es) 2017-10-20 2021-01-08 Pharmabcine Inc Anticuerpo anti-vista y uso del mismo.
CN111386128A (zh) 2017-11-06 2020-07-07 奥瑞基尼探索技术有限公司 用于免疫调节的联合疗法
CN112040959A (zh) 2018-02-23 2020-12-04 真和制药有限公司 通过阻断vista和其结合伴侣的相互作用治疗癌症
BR112020019083A2 (pt) * 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
WO2019185163A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Vista antigen-binding molecules
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
CN109878421B (zh) 2019-03-13 2020-11-03 浙江吉利控股集团有限公司 车辆坡道装置及汽车
CN110563843A (zh) 2019-07-25 2019-12-13 钟小泉 一种靶向人vista蛋白的单克隆抗体

Also Published As

Publication number Publication date
JP7211961B2 (ja) 2023-01-24
CO2019010943A2 (es) 2020-01-17
AU2018236218A1 (en) 2019-09-12
TW201843171A (zh) 2018-12-16
ZA201905525B (en) 2024-12-18
SG11201907848YA (en) 2019-09-27
EP3595720A1 (en) 2020-01-22
TWI890190B (zh) 2025-07-11
US20250206822A1 (en) 2025-06-26
US20200055936A1 (en) 2020-02-20
JP2025023919A (ja) 2025-02-19
AU2018236218B2 (en) 2025-03-06
EP3595720A4 (en) 2021-05-26
JP2020509756A (ja) 2020-04-02
PE20250933A1 (es) 2025-04-02
BR112019019108A2 (pt) 2020-04-22
MX2024003316A (es) 2024-04-04
CN110740749B (zh) 2024-12-10
IL269240A (en) 2019-11-28
CA3054067A1 (en) 2018-09-20
IL326895A (en) 2026-04-01
CL2019002610A1 (es) 2019-11-29
US20240092907A1 (en) 2024-03-21
CL2021002769A1 (es) 2022-08-12
IL269240B1 (en) 2026-04-01
TW202423986A (zh) 2024-06-16
PE20191708A1 (es) 2019-11-28
AU2025203967A1 (en) 2025-07-03
WO2018169993A1 (en) 2018-09-20
JP2023061927A (ja) 2023-05-02
TWI825010B (zh) 2023-12-11
KR102715540B1 (ko) 2024-10-08
KR20240151866A (ko) 2024-10-18
JP7573659B2 (ja) 2024-10-25
US11603406B2 (en) 2023-03-14
CN118894937A (zh) 2024-11-05
CN110740749A (zh) 2020-01-31
US12195535B2 (en) 2025-01-14
KR20190128198A (ko) 2019-11-15

Similar Documents

Publication Publication Date Title
MY200609A (en) Antibodies binding to vista at acidic ph
NZ767596A (en) Antibodies that bind cd39 and uses thereof
MX2021000213A (es) Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acidico.
MX2020009786A (es) Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MY204117A (en) Antibody molecules to cd73 and uses thereof
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
EP4417263A3 (en) Cd3 binding antibodies
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
WO2015067570A3 (en) Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
SG10201808867PA (en) Anti-nme antibody
WO2017019957A3 (en) Binding proteins and methods of use thereof
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2022003204A (es) Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TW202615470A (zh) 在酸性pH結合至VISTA之抗體
EA202092208A1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОТНОМ pH
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
EA202092850A1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH
EA201992139A1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH